Dasanix 50 mg (Tablet)
Unit Price: ৳ 200.00 (6 x 10: ৳ 12,000.00)
Strip Price: ৳ 2,000.00
Medicine Details
Category | Details |
---|---|
Generic | Dasatinib |
Company | Beacon pharmaceuticals plc |
Also available as |
Indications
- Treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
- Treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase
- Treatment of newly diagnosed Ph+ acute lymphoblastic leukemia (ALL)
- Treatment of newly diagnosed Ph+ ALL in combination with chemotherapy
Pharmacology
- Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases
- Modeling studies predicting binding to multiple conformations of the ABL kinase
- Activity in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
- Inhibition of CML and ALL cell lines overexpressing BCR-ABL
- Prediction of overcoming imatinib resistance and multi-drug resistance gene overexpression
Absorption
Cmax observed between 0.5 to 6 hours, increased AUC with high-fat meal
Distribution
- Apparent volume of distribution: 2505 (CV% 93%)
- Binding of Dasatinib to human plasma proteins: approximately 96%
- P-gp substrate in vitro
Elimination
- Mean terminal half-life: 3 to 5 hours
- Apparent oral clearance: 363.8 l/hr (CV% 81.3%)
- Primary metabolism by CYP3A4
- Excretion primarily via feces
Dosage & Administration
- Recommended starting dosage: 100 mg once daily for chronic phase CML in adults, 140 mg once daily for accelerated phase CML or Ph+ ALL in adults
- Recommended starting dosages for pediatric patients based on body weight
- Tablets should not be crushed, cut, or chewed, and can be taken with or without a meal
Interaction
- Strong CYP3A4 inhibitors may increase Dasanix concentrations
- Strong CYP3A4 inducers may decrease Dasanix concentrations
- Coadministration with gastric acid reducing agents may decrease Dasanix concentrations
Contraindications
Known hypersensitivity to Dasatinib or any component of the formulation
Side Effects
- Myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
- Effects on growth and development in pediatric patients
Pregnancy & Lactation
Potential fetal harm, effective contraceptive methods advised for females of reproductive potential, breastfeeding not recommended
Precautions & Warnings
- Severe (NCT CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
Overdose Effects
Experience limited to isolated cases, severe myelosuppression and bleeding reported
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store below 30°C in a dry place, protect from light, keep out of reach of children